KR20210024446A - 인터루킨 12 융합 단백질 및 이의 조성물 및 치료 방법 - Google Patents

인터루킨 12 융합 단백질 및 이의 조성물 및 치료 방법 Download PDF

Info

Publication number
KR20210024446A
KR20210024446A KR1020207033158A KR20207033158A KR20210024446A KR 20210024446 A KR20210024446 A KR 20210024446A KR 1020207033158 A KR1020207033158 A KR 1020207033158A KR 20207033158 A KR20207033158 A KR 20207033158A KR 20210024446 A KR20210024446 A KR 20210024446A
Authority
KR
South Korea
Prior art keywords
fusion protein
seq
subunit
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207033158A
Other languages
English (en)
Korean (ko)
Inventor
양-신 푸
후아 펭
뒤안 쉬에
Original Assignee
이뮨 타켓팅 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮨 타켓팅 인코퍼레이티드 filed Critical 이뮨 타켓팅 인코퍼레이티드
Publication of KR20210024446A publication Critical patent/KR20210024446A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020207033158A 2018-04-25 2019-04-24 인터루킨 12 융합 단백질 및 이의 조성물 및 치료 방법 Ceased KR20210024446A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810376920.1 2018-04-25
CN201810376920.1A CN110396133B (zh) 2018-04-25 2018-04-25 一种以白介素12为活性成分的融合蛋白型药物前体
PCT/US2019/028933 WO2019209965A2 (en) 2018-04-25 2019-04-24 Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof

Publications (1)

Publication Number Publication Date
KR20210024446A true KR20210024446A (ko) 2021-03-05

Family

ID=68294664

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207033158A Ceased KR20210024446A (ko) 2018-04-25 2019-04-24 인터루킨 12 융합 단백질 및 이의 조성물 및 치료 방법

Country Status (9)

Country Link
US (1) US12473337B2 (https=)
JP (2) JP2021521822A (https=)
KR (1) KR20210024446A (https=)
CN (2) CN110396133B (https=)
AU (1) AU2019261411B2 (https=)
BR (1) BR112020021791A2 (https=)
CA (1) CA3097995A1 (https=)
EA (1) EA202092459A1 (https=)
WO (1) WO2019209965A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210017247A1 (en) 2017-07-03 2021-01-21 Torque Therapeutics, Inc. Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
MX2022000991A (es) * 2019-07-25 2022-05-24 Univ Chicago Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
WO2021142471A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
AU2021248919A1 (en) * 2020-04-01 2022-10-13 Xilio Development, Inc. Masked IL-12 cytokines and their cleavage products
WO2022115865A2 (en) * 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
WO2022129313A1 (en) * 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag Precursor proteins and kit for targeted therapy
IL306074A (en) * 2021-03-24 2023-11-01 Alkermes Inc UPAR antibodies and fusion proteins with them
CN117396229A (zh) * 2021-04-21 2024-01-12 Cue生物制药股份有限公司 Mhc ii类t细胞调节多肽及其使用方法
TW202321282A (zh) * 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
JP2024539139A (ja) 2021-10-20 2024-10-28 シンセカイン インコーポレイテッド ヘテロ二量体ｆｃサイトカインおよびその使用
EP4649088A1 (en) * 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
CN121263432A (zh) 2023-04-12 2026-01-02 上海康抗生物技术有限公司 包含掩蔽型白介素12的多功能分子及使用方法
WO2025119304A1 (en) * 2023-12-07 2025-06-12 Wuxi Biologics (Shanghai) Co., Ltd. Heterodimeric proteins against il-12 receptor
WO2025256578A1 (zh) * 2024-06-12 2025-12-18 龙启生物制药(杭州)有限公司 Treg细胞靶向IL12融合蛋白及其制备、治疗方法
WO2026020161A1 (en) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
AU1407997A (en) 1995-12-01 1997-06-19 Beth Israel Hospital Il-12 p40 subunit fusion polypeptides and uses thereof
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998028427A1 (en) 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
JP4718274B2 (ja) 2005-08-25 2011-07-06 東京エレクトロン株式会社 半導体製造装置，半導体製造装置の流量補正方法，プログラム
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
PT3107573T (pt) * 2014-02-19 2019-01-10 Merck Patent Gmbh Imunoterapia com il-12 visada ao cancro
CN105543279A (zh) * 2014-10-30 2016-05-04 常州卡斯比生物科技有限公司 一种防治辐射线损伤、肿瘤治疗的IL-12/Fc融合蛋白的制备方法及其药剂
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
CN105218682B (zh) * 2015-10-26 2019-05-07 杨晶 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
WO2018030806A1 (ko) * 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
MX386014B (es) * 2016-08-10 2025-03-18 Univ Ajou Ind Academic Coop Found Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.

Also Published As

Publication number Publication date
WO2019209965A2 (en) 2019-10-31
US20220162280A1 (en) 2022-05-26
JP2025032113A (ja) 2025-03-11
WO2019209965A3 (en) 2019-12-05
CN112638938A (zh) 2021-04-09
CN110396133B (zh) 2021-07-23
BR112020021791A2 (pt) 2021-02-23
EA202092459A1 (ru) 2021-06-15
CN110396133A (zh) 2019-11-01
CA3097995A1 (en) 2019-10-31
JP2021521822A (ja) 2021-08-30
AU2019261411B2 (en) 2024-11-14
US12473337B2 (en) 2025-11-18
AU2019261411A1 (en) 2020-11-26
EP3810639A2 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
US12473337B2 (en) Homodimeric or heterodimeric interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
JP7684047B2 (ja) インターロイキン１５融合タンパク質、およびその組成物ならびに治療方法
CA2919725C (en) An il-15 and il-15r.aplha. sushi domain based modulokines
US20220402988A1 (en) Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
CA3206549A1 (en) Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
CN118451096A (zh) 异二聚体fc细胞因子及其用途
WO2022015711A1 (en) Fusion proteins of anti-pd-l1 and attenuated interferon, and compositions and therapeutic methods thereof
AU2021202787A1 (en) Combination therapy for the treatment of cancer
CN114456274A (zh) 抗Her-2抗体-趋化因子融合蛋白及其制法和应用
US20260070957A1 (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
HK40050873A (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
HK40050872A (en) Interleukin 15 fusion proteins, and compositions and therapeutic methods thereof
TW202540162A (zh) 含有結合至cldn18.2和cd3之雙特異性結合劑和抗vegfr2抗體之組合療法
HK40074884B (en) Il-15 and il-15ralpha sushi domain based on modulokines
HK40004449B (en) Il-15 and il-15ralpha sushi domain based modulokines

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220401

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240717

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241002

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D